Dental Care Clinics in Elkhorn, NE Accepting Medicare
6 Dental Care Clinics found. Showing 1 - 6
 Shadow Ridge Dental Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 19103 Mason Plz, Elkhorn, NE 68022 Phone: 402-933-0525 Fax: 402-933-2925 |
Dental Professionals Of Nebraska, Pc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 5619 S 204th Ave, Elkhorn, NE 68022 Phone: 531-484-3050 Fax: 531-484-4140 |
Panneton Dental Group Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 18140 Burke St Ste 100, Elkhorn, NE 68022 Phone: 402-934-5200 Fax: 402-537-4346 |
Skyline Pediatric Dentistry Llc Dentist - Pediatric Dentistry Medicare: Not Enrolled in Medicare Practice Location: 1405 N 205th St, Suite 100, Elkhorn, NE 68022 Phone: 402-289-1574 |
Today's Dental Elkhorn Llc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 20211 Manderson Street, Elkhorn, NE 68138 Phone: 402-505-1910 |
Mark Nielsen Dds, Pc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 1908 N 203rd St, Elkhorn, NE 68022 Phone: 402-289-2036 Fax: 402-289-5694 |
News Archive
Opexa Therapeutics reports Q2 2009 financials
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended June 30, 2009, and provided details on further developments.
Blog, forthcoming paper examine PEPFAR's 'financial flows'
Noting the release of the Institute of Medicine's PEPFAR evaluation and "our own work-in-progress on PEPFAR's value for money and data management," Victoria Fan, a research fellow at the Center for Global Development (CGD), and Rachel Silverman, a research assistant at CGD, highlight "two focus areas that ... are the subject of a forthcoming CGD policy paper on PEPFAR's financial flows" in a post on CGD's "Global Health Policy" blog.
Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round
Mercator Therapeutics, the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs, today announced the signing of a license agreement with The University of Texas MD Anderson Cancer Center and the closing of a $2.0 million seed round.
NPS MedicineWise welcomes ABC's decision to take down Catalyst program on statins, heart disease
NPS MedicineWise has welcomed the ABC's ruling — published today — that its Catalyst program aired in October 2013 on statins and heart disease breached its own standards on impartiality.
Laureate Pharma, Selexis SA collaborate to provide streamlined access to complementary contract services
Laureate Pharma, Inc. a US based biopharmaceutical contract manufacturing organization and Selexis SA, a Swiss based contract developer of high performance production cell lines, jointly announced today their continued collaboration via a joint-marketing relationship. This expanded relationship provides streamlined access to a set of highly complementary contract services.
› Verified 5 days ago